Thermo Fisher Scientific (TMO) Equity Average (2009 - 2026)

Thermo Fisher Scientific has disclosed Equity Average across 18 years of filings, most recently posting $52.7 billion for Q1 2026.

• Quarterly Equity Average rose 6.51% year-over-year to $52.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.7 billion (up 6.51% YoY) and the FY2025 annual result came in at $51.5 billion, up 6.95% from the prior year.
• Equity Average improved to $52.7 billion in Q1 2026, from $52.2 billion in the prior quarter.
• Over five years, Equity Average peaked at $52.7 billion in Q1 2026 and troughed at $40.9 billion in Q2 2022.
• A 5-year average of $46.5 billion and a median of $46.1 billion in 2024 frame the typical range for Equity Average.
• Annual changes were most pronounced in 2022 — Equity Average gained 17.66% — and 2023, when it increased 3.29%.
• Tracing TMO's Equity Average over 5 years: stood at $43.8 billion in 2022, then advanced by 5.05% to $46.0 billion in 2023, then rose by 7.01% to $49.3 billion in 2024, then rose by 6.0% to $52.2 billion in 2025, then grew by 0.87% to $52.7 billion in 2026.
• Business Quant data shows TMO's Equity Average at $52.7 billion in Q1 2026, $52.2 billion in Q4 2025, and $50.8 billion in Q3 2025.